Baxter International (NYSE: BAX) Breach of Fiduciary Duties Investigation

Baxter International Breach of Fiduciary Duties Investigation

Contact UsFree Case Evaluation

"*" indicates required fields

First Name*

Last Name*

Email Address*

Phone Number*

Practice Area

City*

State*

Please describe your potential case or matter.**

By clicking SUBMIT you agree to our Terms of Use and Privacy Policy and you are providing express consent to receive communications from Berger Montague via calls, emails, and/or text messages.

Practice Area: Securities Fraud & Investor Protection

Case Status: Pending

Ticker Symbol: NYSE: BAX

Berger Montague is investigating Baxter International’s Board of Directors for potential breaches of fiduciary duties to the Company and its shareholders in connection with Baxter’s marketing and sale of its Novum Large Volume Pump (“Novum LVP”).

Berger Montague’s investigation is focused on whether Baxter’s Board of Directors breached its fiduciary duties in the manner in which it oversaw the Company’s marketing and sale of the Novum LVP, a pump used for the controlled delivery of intravenous fluids, such as blood, medication, and nutrients. In July 2025, Baxter announced that it would “voluntarily and temporarily pause shipments and planned installations of the Novum LVP.”

Shareholders of Baxter may learn more about this investigation by contacting Berger Montague: Radha Raghavan at rraghavan@bergermontague.com or (332) 271-8908, or Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015.